Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

A Phase 1, Multi-Center, Open-Label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics cf CC-94676 In Subjects with Metastatic Castration-Resistant Prostate Cancer


Trial ID:NCT04428788

View complete trial on

Protocol #:20-367

877-DF-TRIAL (877-338-7425)

Condition(s):Prostatic Neoplasms


Principal Investigator:Choudhury, Atish

Site Research Nurse(s):Aspinwall, Sheridan,
Bretta, Katherine, v.
Carey, Margaret, M.
Lagerstedt, Elizabeth,
Leisner, Claire,
Mingrino, Sage,
Pace, Amanda,
Porter, Kathryn,
Prisby, Judith,
Walsh, Meghara,

Trial Description:
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.

Eligibility Requirements:
- Must have histologically or cytologically confirmed adenocarcinoma of the prostate
- Progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
Exclusion Criteria:
- Prior treatment with an androgen receptor (AR) degrader
- Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 1 year prior to the first dose of IP
- Clinically significant venous thromboembolism within 3 months prior to the first dose of IP
- Any significant medical condition, such as uncontrolled infection, laboratory abnormality, or psychiatric illness
Other protocol-defined inclusion/exclusion criteria apply

Protocol #: 20-367

Questions & Enrollment